Wednesday's Top 5 Growth Winners

Ask cheapskate value investors to buy a stock that's achieved a new 52-week high and you'll get one of two responses:

  • Hysterical laughter.
  • Sudden nausea.

Pity them, Fool.

How many times did First Solar (Nasdaq: FSLR  ) touch a new 52-week high on its way to producing eight-bagger returns this year? Lots.

Never assume that "rocket stocks" -- high-growth stocks that are also realizing heavy price appreciation -- are too expensive. What looks like a cliff could really be base camp on a climb towards the summit of Everest.

Rocket stocks, not rocket science
Each weekday in this column, we enlist the more than 78,000 pro and amateur stock pickers in our Motley Fool CAPS community to find stocks that are still climbing. We start with The Wall Street Journal's 52-week high lists. But we focus our search on stocks expected to boost net income by at least 15% a year for the next five years, and whose CAPS ratings sport at least two of the maximum five stars.

Here's what we've turned up today:

Company

Closing Price

CAPS Rating
(5 max)

5-Year
Growth
Estimate

52-Week
Range

Atwood Oceanics (NYSE:ATW)

$91.68

*****

67.0%

$43.77-$92.84

Team (NASDAQ:TISI)

$35.79

*****

23.2%

$13.01-$33.51

LKQ (NASDAQ:LKQX)

$21.26

*****

21.9%

$9.93-$21.74

Bio-Reference Laboratories (NASDAQ:BRLI)

$35.01

*****

18.0%

$21.88-$35.57

Celera Group (NYSE:CRA)

$16.50

***

15.0%

$11.39-$16.55

Sources: The Wall Street Journal, Yahoo! Finance, Motley Fool CAPS.

Our mostly small-cap list features some promising (though speculative) stocks. Yet these tiny titans can create astounding returns if they're bought before the market discovers them. Witness LKQ, which stands for "Like Kind Quality." Shares of the replacement auto parts maker are up 78% over the past 52 weeks. The S&P 500, by contrast, is up just 2% over the same period.

A referral for Bio-Reference
Regional lab Bio-Reference hasn't done quite as well, but is nonetheless up more than 50% since last December.

With our aging population, testing for life-threatening ailments such as cancer has become an in-demand business. Peers LabCorp and Quest Diagnostics (NYSE: DGX  ) are each expected to boost their bottom line by roughly 14% a year over the next five.

Bio-Reference, meanwhile, is growing even faster with esoteric tests doctors use to diagnose difficult cases. The strategy is paying off. Last night, Bio-Reference reported a 29% increase in fourth-quarter revenue and a 22% gain in diluted per-share income. That's roughly consistent with its third-quarter results, in which Bio-Reference posted a 35% year-over-year improvement in revenue and a 14% increase in diluted earnings per share.

If there's a problem with Bio-Reference it's with valuation. Analysts have tagged the shares with a 1.95 PEG ratio -- a healthy premium to both LabCorp and Quest. I'd prefer to see the reverse.

But I also take solace in who owns a piece of the business. Joel Tillinghast, a superstar bargain shopper and manager of Fidelity Low-Priced Stock (FLPSX), owns more shares than any other fund. Insiders, meanwhile, still have a 17% stake in Bio-Reference.

I can't ignore that sort of support; Bio-Reference joins my CAPS watch list today. But that's me. What's your take? Would you buy Bio-Reference at today's prices? Let us know by signing up for CAPS now. It's 100% free to participate.

I'll be back tomorrow with more rocket stocks.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 557172, ~/Articles/ArticleHandler.aspx, 8/27/2014 3:29:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement